Natera Presents New Signatera Data Showing High Sensitivity in Multiple Cancers
Natera presented data at ASTRO 2026 showcasing the risk stratification and monitoring utility of its Signatera test. The data indicated 100% sensitivity and 97% specificity in locally advanced rectal cancer, and demonstrated Signatera's ability to provide ctDNA lead time to recurrence in vulvovaginal cancer.